Cleveland Clinic Lerner COM, Cleveland Clinic, Cleveland, OH, USA;
Int J Womens Health. 2010 Aug 9;2:37-44. doi: 10.2147/ijwh.s4919.
One out of every 2 women within postmenopause are at risk of fracture due to osteoporosis. Fortunately, a growing arsenal of therapies is becoming available to treat this disease and prevent fracture. A new class of anabolic agents has emerged within the last decade that brought with it a new concept in osteoporosis therapy: building new stronger bone rather than simply inhibiting bone turnover. Evidence is accumulating to understand how to best utilize these new agents, and which patients benefit most. This article will review the effectiveness, risks, timing and clinical uses of teriparatide in postmenopausal osteoporosis.
每两名绝经后女性中就有一名面临因骨质疏松而骨折的风险。幸运的是，越来越多的治疗方法正被应用于治疗这种疾病和预防骨折。在过去十年中，出现了一类新的合成代谢药物，为骨质疏松症的治疗带来了一个新概念：即建立新的更强壮的骨骼，而不仅仅是抑制骨转换。目前正在积累更多的证据来了解如何最好地利用这些新的药物，以及哪些患者最受益。本文将综述特立帕肽治疗绝经后骨质疏松症的有效性、风险、时机和临床应用。
